G. Guetens

863 total citations
23 papers, 658 citations indexed

About

G. Guetens is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, G. Guetens has authored 23 papers receiving a total of 658 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Molecular Biology and 6 papers in Cancer Research. Recurrent topics in G. Guetens's work include Cancer, Hypoxia, and Metabolism (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers) and Angiogenesis and VEGF in Cancer (4 papers). G. Guetens is often cited by papers focused on Cancer, Hypoxia, and Metabolism (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers) and Angiogenesis and VEGF in Cancer (4 papers). G. Guetens collaborates with scholars based in Belgium, Netherlands and United States. G. Guetens's co-authors include E. A. de Bruijn, Gert De Boeck, A.T. van Oosterom, Hans Wildiers, Willy Landuyt, Eric Verbeken, Bart Landuyt, R. A. A. Maes, Martin Highley and Hans Prenen and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, British Journal of Cancer and Annals of Oncology.

In The Last Decade

G. Guetens

23 papers receiving 637 citations

Peers

Countries citing papers authored by G. Guetens

Since Specialization

Citations

This map shows the geographic impact of G. Guetens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Guetens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Guetens more than expected).

Fields of papers citing papers by G. Guetens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Guetens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Guetens. The network helps show where G. Guetens may publish in the future.

Co-authorship network of co-authors of G. Guetens

This figure shows the co-authorship network connecting the top 25 collaborators of G. Guetens. A scholar is included among the top collaborators of G. Guetens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Guetens. G. Guetens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Selective pulmonary artery perfusion with melphalan is equal to isolated lung perfusion but superior to intravenous melphalan for the treatment of sarcoma lung metastases in a rodent model 2012 ·European Journal of Cardio-Thoracic Surgery ·W. Hengst, Jeroen Hendriks, Tom Van Hoof, (unknown), G. Guetens, Gert De Boeck, Filip Lardon, Paul Van Schil	8
2	Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib 2006 ·Clinical Pharmacology & Therapeutics ·Erin R. Gardner, Henry Burger, R VANSCHAIK, (unknown), (unknown), G. Guetens, Hans Prenen, (unknown), Sharyn D. Baker, Susan E. Bates	107
3	Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study 2006 ·Anti-Cancer Drugs ·Herlinde Dumez, Marc Martens, (unknown), G. Guetens, Gert De Boeck, (unknown), E. A. de Bruijn, R. A. A. Maes, Allan T. van Oosterom	18
4	A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours 2006 ·Annals of Oncology ·Herlinde Dumez, Ahmad Awada, Martine Piccart, Sylvie Assadourian, Dorothée Sémiond, G. Guetens, Gert De Boeck, R. A. A. Maes, E. A. de Bruijn, A. van Oosterom	15
5	Balloon catheter hypoxic pelvic perfusion with mitomycin C and melphalan for locally advanced tumours in the pelvic region: A phase I—II trial 2005 ·European Journal of Surgical Oncology ·Marc G. A. van Ijken, Boudewijn van Etten, G. Guetens, E. A. de Bruijn, Timo L.M. ten Hagen, Th. Wiggers, A.M.M. Eggermont	8
6	Biochemotherapeutic strategies and the (dis) utility of hypoxic perfusion of liver, abdomen and pelvis using balloon catheter techniques 2005 ·European Journal of Surgical Oncology ·Marc G. A. van Ijken, Boudewijn van Etten, Flávia Brunstein, Timo L.M. ten Hagen, G. Guetens, Johannes H. W. de Wilt, E. A. de Bruijn, Alexander M.M. Eggermont	3
7	Sensitive and specific quantification of the anticancer agent ZD1839 (Gefitinib) in plasma by on-column focusing capillary liquid chromatography–tandem mass spectrometry 2005 ·Journal of Chromatography A ·G. Guetens, Hans Prenen, Gert De Boeck, Walter Van Dongen, Eddy L. Esmans, Filip Lemière, A.T. van Oosterom, Patrick Schöffski, E. A. de Bruijn	13
8	Anterograde versus retrograde isolated lung perfusion with melphalan in the WAG-Rij rat 2005 ·European Journal of Cardio-Thoracic Surgery ·(unknown), Jeroen Hendriks, (unknown), Joost Weyler, G. Guetens, (unknown), (unknown), (unknown)	5
9	Synergistic Antitumor Activity of Histamine Plus Melphalan in Isolated Limb Perfusion: Preclinical Studies 2004 ·JNCI Journal of the National Cancer Institute ·Flávia Brunstein, Saske Hoving, Ann L.B. Seynhaeve, Sandra T. van Tiel, G. Guetens, E. A. de Bruijn, Alexander M.M. Eggermont, Timo L.M. ten Hagen	32
10	Balloon catheter hypoxic abdominal perfusion with Mitomycin C and Melphalan for locally advanced pancreatic cancer: a phase I–II trial 2004 ·European Journal of Surgical Oncology ·Marc G. A. van Ijken, Boudewijn van Etten, G. Guetens, Timo L.M. ten Hagen, Johannes Jeekel, E. A. de Bruijn, Alexander M.M. Eggermont, Casper H.J. van Eijck	14
11	Variations in Flow, Duration, and Concentration Do Not Change the Final Lung Concentration of Melphalan after Isolated Lung Perfusion in Rats 2003 ·European Surgical Research ·(unknown), Jeroen Hendriks, Bart P. van Putte, G. Guetens, E. A. de Bruijn, Paul Van Schil	3
12	Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-α-based isolated hepatic perfusion 2003 ·British Journal of Cancer ·Boudewijn van Etten, Mark R. de Vries, Marc G. A. van Ijken, Titia E. Lans, G. Guetens, (unknown), Sandra T. van Tiel, Gert De Boeck, E. A. de Bruijn, Alexander M.M. Eggermont, Timo L.M. ten Hagen	39
13	Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11 2003 ·British Journal of Cancer ·Hans Wildiers, G. Guetens, Gert De Boeck, Eric Verbeken, Bart Landuyt, Willy Landuyt, E. A. de Bruijn, A.T. van Oosterom	252
14	Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence 2003 ·European Journal of Cancer ·Hans Wildiers, (unknown), G. Guetens, Gert De Boeck, E. A. de Bruijn, Willy Landuyt, A.T. van Oosterom	13
15	Melphalan availability in hypoxia‐inducible factor‐1α^+/+ and factor‐1α^–/– tumors is independent of tumor vessel density and correlates with melphalan erythrocyte transport 2002 ·International Journal of Cancer ·Hans Wildiers, G. Guetens, Gert De Boeck, Willy Landuyt, Eric Verbeken, Martin Highley, E. A. de Bruijn, Allan T. van Oosterom	8
16	Hyphenated techniques in anticancer drug monitoring 2002 ·Journal of Chromatography A ·G. Guetens, Gert De Boeck, Martin Highley, Michelle Wood, R. A. A. Maes, A Eggermont, A.-R. Hanauske, E. A. de Bruijn, U.R. Tjaden	22
17	Hyphenated techniques in anticancer drug monitoring 2002 ·Journal of Chromatography A ·G. Guetens, Gert De Boeck, Michelle Wood, R. A. A. Maes, A Eggermont, Martin Highley, A.T. van Oosterom, E. A. de Bruijn, U. R. Tjaden	16
18	Quantitation of suspensions (MESED). Application of MESED-gC/MS in the quantitation of ifosfamide mustard in erythrocytes, plasma, and plasma water 2001 ·Journal of Separation Science ·Herlinde Dumez, G. Guetens, Gert De Boeck, Martin Highley, U.R. Tjaden, R. A. A. Maes, A.-R. Hanauske, A.T. van Oosterom, E. A. de Bruijn	3
19	Nanotechnology in bio/clinical analysis 2000 ·Journal of Chromatography B Biomedical Sciences and Applications ·G. Guetens, K. Van Cauwenberghe, Gert De Boeck, R. A. A. Maes, U.R. Tjaden, J. van der Greef, Martin Highley, A.T. van Oosterom, E. A. de Bruijn	48
20	Simultaneous determination of the peptide-mitomycin KW-2149 and its metabolites in plasma by high-performance liquid chromatography 2000 ·Journal of Chromatography B Biomedical Sciences and Applications ·(unknown), G. Guetens, Gert De Boeck, K. Van Cauwenberghe, R. A. A. Maes, C Ardiet, A.T. van Oosterom, Martin Highley, E. A. de Bruijn, U.R. Tjaden	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact